- Home
- XBP vs ACXP Comparison
XBP vs ACXP Comparison
Compare XBP & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XBP | ACXP |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.7M | 6.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | XBP | ACXP |
|---|---|---|
| Price | $5.32 | $3.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $143.67 |
| AVG Volume (30 Days) | 31.5K | ★ 78.0K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $62,823,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.11 | $3.17 |
| 52 Week High | $25.60 | $25.00 |
Technical Indicators
Market Signals| Indicator | XBP | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 87.96 | 39.72 |
| Support Level | $0.41 | $3.98 |
| Resistance Level | $6.70 | $4.36 |
| Average True Range (ATR) | 0.20 | 0.36 |
| MACD | 0.57 | 0.04 |
| Stochastic Oscillator | 78.06 | 21.60 |
Price Performance
Historical ComparisonAbout XBP XBP Europe Holdings Inc.
XBP Global Holdings Inc is a multinational leader in business process automation, serving over 2,500 clients-including more than 30 Fortune 100 companies. Its proprietary software and deep domain expertise position it as a trusted technology and services partner. With cloud-based solutions and a global footprint, XBP Global delivers measurable value, improves advances digital transformation, improves market-wide liquidity by expediting payments, and promotes sustainable business practices.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.